A Markov chain model evaluated the cost-effectiveness of abemaciclib and ribociclib with letrozole compared with letrozole alone for HR+/HER2– EBC from a payer perspective in India. Key measures ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback